Jae Ho Jeong
University of Ulsan
CancerInternal medicineOncologyRetrospective cohort studyHazard ratioMetastatic breast cancerChemotherapyNeutropeniaFOLFIRINOXTamoxifenCisplatinMetastasisEverolimusPancreatic cancerGemcitabineIrinotecanFluorouracilBiliary tract cancerIn patientCancer researchBreast cancerMedicineGastroenterology
66Publications
8H-index
245Citations
Publications 65
Newest
#1Hyehyun Jeong (UOU: University of Ulsan)H-Index: 4
#2Jae Ho Jeong (UOU: University of Ulsan)H-Index: 8
Last. Sung-Bae Kim (UOU: University of Ulsan)H-Index: 57
view all 0 authors...
Purpose In hormone receptor-positive, HER2-negative metastatic breast cancer (HR+ HER2- MBC), the mainstay treatment options include cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and everolimus (EVE) in combination with endocrine treatment. This study aims to compare the outcomes of the following treatment sequences: CDK4/6i followed by EVE and EVE followed by CDK4/6i. Materials and Methods Data from HR+ HER2- MBC patients treated between Jan. 2014 and Nov. 2020 with both CDK4/6i and EVE were...
Source
PURPOSE More than half of patients with bile duct cancer (BDC) develop recurrence even after curative resection. Recurrent BDC has a poor prognosis, and no optimal treatment modality has been established. We therefore analyzed our experience on the survival outcomes of radiation therapy (RT) for recurrent extrahepatic bile duct cancer (EHBDC). PATIENTS AND METHODS We retrospectively analyzed the records of patients with recurrent EHBDC who underwent concurrent chemoradiation therapy (CCRT) or RT...
Source
#5Jong Won Lee (UOU: University of Ulsan)H-Index: 35
Source
#1Giulia RovestiH-Index: 7
#2Francesco LeoneH-Index: 22
Last. Andrea Casadei-Gardini (UniSR: Vita-Salute San Raffaele University)H-Index: 11
view all 29 authors...
BACKGROUND AND AIM The need to estimate prognosis of advanced BTC (aBTC) patients treated with first-line chemotherapy is compelling. The aim of the study is to evaluate the ECSIPOT (psECogSIiPnigOT) index, influenced by PECS (PsECogSii) index, prognostic nutritional index (PNI), and GOT. METHODS This international study was conducted on a training cohort of 126 patients and in three validation cohorts, both European and Korean. ECSIPOT index formula: (PECS:0 = 1 point; PECS:1 = 1.4 points; PECS...
Source
#9Ji Sung Lee (UOU: University of Ulsan)H-Index: 3
Source
#2Jae Ho JeongH-Index: 8
Last. Jeong Eun KimH-Index: 1
view all 9 authors...
Source
#2Jae Ho JeongH-Index: 8
Last. S-B KimH-Index: 11
view all 13 authors...
Source
#1Jae Ho JeongH-Index: 8
Last. S-B KimH-Index: 11
view all 6 authors...
Source
#1Zhen-Yu Wu (Tongji University)H-Index: 2
#2Youngjin Lee (UOU: University of Ulsan)H-Index: 2
Last. BeomSeok Ko (UOU: University of Ulsan)H-Index: 5
view all 13 authors...
Background: In patients with hormone receptor-positive (HR+)/premenopausal breast cancer, luteinizing hormone-releasing hormone analogs (LHRHas) are used as standard endocrine treatment. Based on previous clinical studies, 1-month formulations are recommended in most breast cancer treatment guidelines, but long-acting formulations facilitate reductions in side effects and patient discomfort caused by frequent administration. However, few efficacy studies have been conducted on 6-month formulatio...
Source
#1Hyehyun Jeong (UOU: University of Ulsan)H-Index: 4
#2Jae Ho Jeong (UOU: University of Ulsan)H-Index: 8
Last. Sung-Bae Kim (UOU: University of Ulsan)H-Index: 57
view all 13 authors...
The phase 2 LEO study showed that everolimus (EVE) plus letrozole (LET) with ovarian suppression increased progression-free survival (PFS) in tamoxifen-exposed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer with visceral metastases. Here we report final survival outcomes from the LEO study, and the results of exploratory analyses of bone turnover marker changes and bone-specific progressive disease. Patients who were exposed to or progressed on tamoxif...
1 CitationsSource